Finally, we conducted a drug sensitivity analysis and found that high ESPL1 expression was associated with an elevated IC50 of paclitaxel (p = 0.016) and a low IC50 of gemcitabine (p = 0.0012) in BC patients (Fig. 9B). Here, ESPL1 is linked to breast cancer.